Enwei Pharmaceutical Co (SZSE:301331) Inventories, Raw Materials & Components: ¥0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301331 Enwei Pharmaceutical Co Ltd SZSE:301331
76 GF Score
Price ¥21.84
GF Value ¥28.16
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Enwei Pharmaceutical Co Inventories, Raw Materials & Components?

Enwei Pharmaceutical Co SZSE:301331 -0.86% 76 Inventories, Raw Materials & Components is ¥0.0 Mil as of Mar. 2026. GuruFocus rates SZSE:301331 with a GF Score™ of 76/100 and a GF Value™ of ¥28.16 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Enwei Pharmaceutical Co's inventories, raw materials & components for the quarter that ended in Mar. 2026 was ¥0.0 Mil.

Enwei Pharmaceutical Co's quarterly raw materials increased from Sep. 2025 (¥0.0 Mil) to Dec. 2025 (¥24.7 Mil) but then declined from Dec. 2025 (¥24.7 Mil) to Mar. 2026 (¥0.0 Mil).

Enwei Pharmaceutical Co's annual raw materials increased from Dec. 2023 (¥30.1 Mil) to Dec. 2024 (¥31.0 Mil) but then declined from Dec. 2024 (¥31.0 Mil) to Dec. 2025 (¥24.7 Mil).

Enwei Pharmaceutical Co Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Enwei Pharmaceutical Co's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enwei Pharmaceutical Co Inventories, Raw Materials & Components Chart

Enwei Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only 164.20 38.04 30.07 31.00 24.69

Enwei Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 28.64 0.00 24.69 0.00
SZSE:301331
76GF Score
Enwei Pharmaceutical Co Ltd SZSE:301331
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enwei Pharmaceutical Co Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of ¥0.0 Mil mean?
Enwei Pharmaceutical Co (SZSE:301331) has a Inventories, Raw Materials & Components of ¥0.0 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Enwei Pharmaceutical Co and its competitors.
Is Enwei Pharmaceutical Co's Inventories, Raw Materials & Components too high?
Enwei Pharmaceutical Co's current Inventories, Raw Materials & Components is ¥0.0 Mil. Overall, Enwei Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enwei Pharmaceutical Co's Inventories, Raw Materials & Components compare to ZTS?
Enwei Pharmaceutical Co's Inventories, Raw Materials & Components of ¥0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Enwei Pharmaceutical Co and its competitors. Enwei Pharmaceutical Co's current Inventories, Raw Materials & Components is ¥0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enwei Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Enwei Pharmaceutical Co (SZSE:301331) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.16, compared to a current price of ¥21.84 — trading 22.4% below its estimated fair value. The current Inventories, Raw Materials & Components is ¥0.0 Mil. Enwei Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Enwei Pharmaceutical Co (SZSE:301331), the current Inventories, Raw Materials & Components is ¥0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enwei Pharmaceutical Co (SZSE:301331) Overvalued in 2026?

Based on GuruFocus' analysis, Enwei Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥21.84 is trading 22.4% below its estimated GF Value™ of ¥28.16. GuruFocus considers Enwei Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SZSE:301331:

  • Inventories, Raw Materials & Components: ¥0.0 Mil
  • GF Value™: ¥28.16 vs. price of ¥21.84 (22.4% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the SZSE:301331 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enwei Pharmaceutical Co Business Description

Address No. 458, Section 3, Shuanghua Road, Shuangliu District, Chengdu, Sichuan Province, Changdu, CHN, 610200
Enwei Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of proprietary Chinese medicines and chemical medicines. The company mainly procures Chinese medicinal herbs, processed Chinese medicinal herbs, chemical raw materials, excipients, packaging materials, plastics, and other miscellaneous items.
76GF Score

Get the complete analysis for SZSE:301331

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥21.84
Price
¥28.16
GF Value